Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Rhumbline Advisers raised its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 24.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 53,172 shares of the company’s stock after purchasing an additional 10,290 shares during the period. Rhumbline Advisers owned 0.10% of Cardiff Oncology worth $231,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. HB Wealth Management LLC acquired a new stake in shares of Cardiff Oncology in the 4th quarter valued at about $105,000. Barclays PLC boosted its holdings in Cardiff Oncology by 291.9% in the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after acquiring an additional 39,542 shares in the last quarter. Geode Capital Management LLC grew its stake in Cardiff Oncology by 1.9% in the third quarter. Geode Capital Management LLC now owns 928,232 shares of the company’s stock valued at $2,479,000 after acquiring an additional 17,557 shares during the period. XTX Topco Ltd increased its holdings in shares of Cardiff Oncology by 44.3% during the third quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock valued at $321,000 after acquiring an additional 36,947 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Cardiff Oncology by 3.4% during the third quarter. State Street Corp now owns 832,652 shares of the company’s stock valued at $2,223,000 after acquiring an additional 27,628 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

Analyst Upgrades and Downgrades

CRDF has been the topic of a number of recent research reports. HC Wainwright increased their target price on Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Piper Sandler raised their price objective on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday, December 13th.

Cardiff Oncology Stock Performance

Shares of CRDF opened at $3.86 on Monday. The firm has a market capitalization of $197.38 million, a P/E ratio of -4.11 and a beta of 1.73. Cardiff Oncology, Inc. has a 52 week low of $2.01 and a 52 week high of $6.42. The stock has a 50 day moving average price of $4.04 and a two-hundred day moving average price of $3.30.

Insider Activity at Cardiff Oncology

In related news, Director Gary W. Pace acquired 350,115 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the purchase, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. The trade was a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.80% of the stock is owned by insiders.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.